Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05307991
Other study ID # 21-2457
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 9, 2022
Est. completion date August 1, 2023

Study information

Verified date April 2023
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective cohort study evaluating acceptability, feasibility, and effectiveness of integrating HIV pre-exposure prophylaxis (PrEP) into a sexually transmitted infection (STI) clinic alongside assisted partner notification and etiologic STI testing in Lilongwe, Malawi.


Recruitment information / eligibility

Status Completed
Enrollment 249
Est. completion date August 1, 2023
Est. primary completion date August 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 15 Years and older
Eligibility Patient Participant Inclusion Criteria: - =15 years of age. - Eligible for PrEP according to Malawi PrEP guidelines (see below) - Presenting for care at STI clinic (primary presentation or referral from partner based on STI or HIV exposure) - Able to consent for study participation and willing to provide locator information for follow-up tracing *Malawi PrEP eligibility criteria: - Age =15 years - HIV seronegative iii. At substantial risk for HIV, with prioritization of persons who: - Buy or sell sex; Key population (female sex worker, men who have sex with other men, transgendered persons; Vulnerable population included adolescent girls and young women aged 15-24; STI clients; Serodiscordant couples including HIV-negative women who are pregnant or breast feeding or HIV-negative men or women for whom their HIV-infected partner is: not on ART, on ART <6 months, has an unsuppressed or high viral load, or is non-adherent to ART, iv. Have ruled out acute HIV infection, or defer PrEP initiation for anyone with signs or symptoms consistent with acute HIV infection, v. Willingness to attend scheduled PrEP visits, vi. No contraindication to use of TDF and 3TC, vii. Bodyweight =30 kg, viii. Estimated glomerular filtration rate (eGFR) =60mL/min, ix. No known renal diseases, x. No diabetes mellitus. Exclusion Criteria: - Current imprisonment or incarceration in a medical or psychiatric facility Provider Participant: Inclusion Criteria: - =18 years of age. - Duties relevant to integration or provision of PrEP and/or aPN at STI clinic Exclusion Criteria: - Unable or unwilling to provide informed consent

Study Design


Intervention

Drug:
PrEP
HIV pre-exposure prophylaxis (or PrEP) will include the Malawi-approved PrEP regimen at time of study enrollment. At time of submission, the only Malawi-approved regimen includes Tenofovir/emtricitabine (TDF/FTC) containing 300 mg of TDF and 200 mg of FTC. If additional PrEP regimens become available in Malawi during the study recruitment or follow-up, participants will be able to choose from any regimen that they are eligible to receive per Malawi PrEP guidelines.
Device:
STI testing
Urine specimens will be tested for Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (GC) using GeneXpert® (Cepheid, Sunnyvale, CA) Xpert® CT/GC platform and cartridge and syphilis RPR titer (BD Macro-VUE™, Becton, Dickinson and Company, Franklin Lakes, NJ [FDA approved]) with confirmatory Treponema pallidum particle agglutination (TP-PA) (Serodia Fujirebio Inc, Malvern, PA [CE mark]) if RPR is positive.
Behavioral:
Assisted partner notification
Participants will be asked to provide the name and locator information for all sexual partners in the preceding 6 months. Participants will be asked to refer sexual partners to the clinic and will be provided with cards to distribute to partners. Each card will request that the recipient report to the STI clinic with the card and will contain a linking number that links them back to the index participant. Sexual Partner Tracing: In accordance with the contract referral approach, if the named partners do not present to an STI clinic within 7-14 days, community outreach workers will contact the partners and counsel them to visit the clinic. Contact may be made through telephone, text message, or in person, as needed and will not disclose the name or identify of the index patient.
Diagnostic Test:
Acute HIV testing
Persons initiating or re-initiating PrEP will also be screened for acute HIV infection (AHI) using Abbott RealTime HIV-1 Assay (Abbott Laboratories, Chicago, IL) or Xpert® HIV-1 Viral Load (GeneXpert, Cepheid, Sunnyvale, CA).

Locations

Country Name City State
Malawi Bwaila STI clinic Lilongwe

Sponsors (1)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill

Country where clinical trial is conducted

Malawi, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of participants retained on PrEP Examine the proportion of participants who initiate PrEP at enrollment who are retained on PrEP through study completion (6 months) Approximately 6 months after enrollment
Primary Number of participants retained on PrEP Examine the number of participants who initiate PrEP at enrollment who are retained on PrEP through study completion (6 months) Approximately 6 months after enrollment
Primary Number of provider participants describing feasibility of aPN and STI testing (qualitative) To gain deeper insights about the feasibility of enhanced PrEP delivery, PrEP providers from the study site will be asked to participate in in-depth interviews. Participating providers are involved in different aspects of PrEP provision, aPN, and STI testing and include study staff members. Feasibility is defined as a positive rating about the intervention's potential performance in real-life conditions at the clinic and community levels. Approximately 6 months after the start of enrollment
Primary Number of provider participants describing feasibility of aPN and STI testing (quantitative) To gain deeper insights about the feasibility of enhanced PrEP delivery, PrEP providers from the study site will be asked to complete survey using modified validated measures assessing feasibility on a 5-point Likert scale. Participating providers are involved in different aspects of PrEP provision, aPN, and STI testing and include study staff members. Approximately 6 months after the start of enrollment
Primary Number of provider participants describing acceptability of aPN and STI testing (quantitative) To gain deeper insights about the acceptability of enhanced PrEP delivery, PrEP providers from the study site will be asked to complete survey using modified validated measures assessing feasibility on a 5-point Likert scale. Participating providers are involved in different aspects of PrEP provision, aPN, and STI testing and include study staff members. Approximately 6 months after the start of enrollment
Primary Number of provider participants describing acceptability of aPN and STI testing (qualitative) To gain deeper insights about the acceptability of enhanced PrEP delivery, PrEP providers from the study site will be asked to participate in in-depth interviews. Participating providers are involved in different aspects of PrEP provision, aPN, and STI testing and include study staff members. Acceptability is defined as a positive rating about the intervention's potential performance in real-life conditions at the clinic and community levels. Approximately 6 months after the start of enrollment
Primary Number of patient participants describing acceptability of aPN and STI testing (qualitative) To gain deeper insights about the acceptability of enhanced PrEP delivery from the patient perspective, as subset of enrolled patients (including persons who initiate PrEP [index], referred partners who initiate PrEP, and persons who decline PrEP) will be asked to participate in in-depth interviews. Acceptability is defined as a positive rating about the intervention's potential performance in real-life conditions at the clinic and community levels. Approximately 6 months after enrollment
Primary Number of patient participants describing acceptability of aPN and STI testing (quantitative) To gain deeper insights about the acceptability of enhanced PrEP delivery from the patient perspective, participants will be asked a series of questions using modified validated measures assessing acceptability on a 4-point Liker scale. Acceptability is defined as a positive rating about the intervention's appeal. Approximately 6 months after enrollment
Primary Number of patient participants describing feasibility of aPN and STI testing (qualitative) To gain deeper insights about the feasibility of enhanced PrEP delivery from the patient perspective, as subset of enrolled patients (including persons who initiate PrEP [index], referred partners who initiate PrEP, and persons who decline PrEP) will be asked to participate in in-depth interviews. Acceptability is defined as a positive rating about the intervention's potential performance in real-life conditions at the clinic and community levels. Approximately 6 months after enrollment
Secondary Number of STI clinic patients eligible for PrEP The number of STI clinic patients who would meet Malawi PrEP eligibility according to pre-defined criteria Approximately 1 year
Secondary Proportion of STI clinic patients eligible for PrEP The proportion of STI clinic patients who would meet Malawi PrEP eligibility Approximately 1 year
Secondary Number of PrEP eligible STI clinic patients referred for PrEP The number of PrEP eligible STI clinic patients who are referred for PrEP services Approximately 1 year
Secondary Proportion of PrEP eligible STI clinic patients referred for PrEP The proportion of PrEP eligible STI clinic patients who are referred for PrEP services Approximately 1 year
Secondary Number of PrEP eligible STI clinic patients declining PrEP Reasons for declining PrEP will be reported qualitatively in order to inform future studies. Approximately 1 year
Secondary Number of PrEP-eligible patients starting PrEP within 7-days of STI screening The number of PrEP-eligible patients starting PrEP within 7-days of presenting for initial STI screening Approximately 1 year
Secondary Proportion of PrEP-eligible patients starting PrEP within 7-days of STI screening The proportion of PrEP-eligible patients starting PrEP within 7-days of presenting for initial STI screening Approximately 1 year
Secondary Proportion of all participants retained on PrEP The proportion of participants (including persons who initiate PrEP [index], referred partners who initiate PrEP, and persons who initially decline PrEP but start during study follow-up) who are retained on PrEP at 1, 3, and 6 months of follow-up. Up to approximately 6 months
Secondary Proportion of enrolled PrEP users naming at least one recent sex partner The proportion of PrEP users who name at least one recent sex partner, defined as having had sex with them in the prior 6 months, for assisted partner notification Up to approximately 6 months
Secondary Number of named partners screened for PrEP eligibility The number of named partners who return for PrEP screening using either passive notification or those who return only after tracing Approximately 1 year
Secondary Proportion of named partners screened for PrEP eligibility The proportion of named partners who return for PrEP screening using either passive notification or those who return only after tracing Approximately 1 year
Secondary Number of named partners screened for PrEP eligibility who are ineligible for PrEP Among partners presenting for screening, the number of named partners who are ineligible for PrEP. Approximately 1 year
Secondary Proportion of named partners screened for PrEP eligibility who are ineligible for PrEP Among partners presenting for screening, the proportion of named partners who are ineligible for PrEP. Approximately 1 year
Secondary Number of PrEP-eligible named partners who initiate PrEP Among PrEP-eligible partners who present to the clinic, the number who agree to initiate PrEP Approximately 1 year
Secondary Proportion of PrEP-eligible named partners who initiate PrEP Among PrEP-eligible partners who present to the clinic, the proportion who agree to initiate PrEP Approximately 1 year
Secondary Number of PrEP-eligible named partners who decline PrEP Reasons for declining PrEP will be reported qualitatively in order to inform future studies. Approximately 1 year
Secondary Proportion of consenting eligible patient participants who receive STI testing The proportion of all participants who receive STI testing at baseline, 0, 3, and 6 months Up to approximately 6 months
Secondary Proportion of participants who receive appropriate STI treatment within 7 days of testing The proportion of all patient participants who receive indicated treatment, based on results of etiologic STI testing, within 7 days of having been tested Up to approximately 6 months
Secondary Proportion of participants with symptomatic STI The proportion of all patient participants (including persons who initiate PrEP [index], referred partners who initiate PrEP, and persons who initially decline PrEP) who have a symptomatic STI at enrollment, 1, 3, or 6 months Up to approximately 6 months
Secondary Proportion of participants with asymptomatic STI The proportion of all patient participants (including persons who initiate PrEP [index], referred partners who initiate PrEP, and persons who initially decline PrEP) who have an asymptomatic STI at enrollment, 1, 3, or 6 months Up to approximately 6 months
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2